Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies

CD27, a costimulatory molecule on T cells, induces intracellular signals mediating cellular activation, proliferation, effector function, and cell survival on binding to its ligand, CD70. Varlilumab, a novel, first-in-class, agonist immunoglobulin G1 anti-CD27 antibody, mediates antitumor immunity a...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Adv
Päätekijät: Ansell, Stephen M., Flinn, Ian, Taylor, Matthew H., Sikic, Branimir I., Brody, Joshua, Nemunaitis, John, Feldman, Andrew, Hawthorne, Thomas R., Rawls, Tracey, Keler, Tibor, Yellin, Michael J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2020
Aiheet:
Immunobiology and Immunotherapy
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7218437/
https://ncbi.nlm.nih.gov/pubmed/32380537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001079
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia